Cegfila (previously Pegfilgrastim Mundipharma)



This medicine is authorised for use in the European Union.


Pegfilgrastim Mundipharma is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer chemotherapy and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever due to an infection). 

Pegfilgrastim Mundipharma is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).

Pegfilgrastim Mundipharma is a ‘biosimilar medicine’. This means that Pegfilgrastim Mundipharma is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Pegfilgrastim Mundipharma is Neulasta. For more information on biosimilar medicines, see 'Related content' below.

Pegfilgrastim Mundipharma contains the active substance pegfilgrastim.

This EPAR was last updated on 12/02/2020

Authorisation details

Product details
Cegfila (previously Pegfilgrastim Mundipharma)
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Publication details
Marketing-authorisation holder
Mundipharma Biologics S.L.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Calle García Ximénez, nº3-1º
31002 Pamplona (Navarra)

Product information

06/02/2020 Cegfila (previously Pegfilgrastim Mundipharma) - EMEA/H/C/005312 - IAIN/0002


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Assessment history

How useful was this page?

Add your rating